AB 242 revises section 124977 of the California Health and Safety Code to reshape financing and administrative authority for the state's genetic disease testing program. It reinforces the program’s fee-based funding model, creates a distinct Birth Defects Monitoring Program Fund for prenatal screening fees, and directs the department to implement fee collection and invoicing systems.
Beyond funding, the bill expands the department’s operational leeway: it carves out specific procurement and IT approval exemptions for program purchases and system expansions and authorizes emergency regulation procedures that bypass ordinary Office of Administrative Law review. The changes affect hospitals, payers, researchers, and vendors who work with the state screening program and raise implementation, equity, and oversight questions for compliance officers and legal teams.
At a Glance
What It Does
The bill authorizes the department to charge fees to all payers for tests and related activities, creates the Birth Defects Monitoring Program Fund to receive prenatal screening fees, requires the department to implement fee-collection infrastructure, and prescribes invoicing rules for researchers requesting samples or data. It also exempts certain expenditures from specified Public Contract Code and state IT approval requirements and allows the department to adopt emergency regulations without Office of Administrative Law review, filing them directly with the Secretary of State.
Who It Affects
Hospitals of birth (and families for non‑hospital births), health plans and insurers that cover prenatal and newborn screening, the Department of Public Health and its genetic disease branch, researchers requesting access to stored pregnancy blood samples, and contractors/vendors providing IT, testing equipment, or followup services.
Why It Matters
The bill converts program operations into a more self-sustaining, fee-driven enterprise and accelerates the department’s ability to add tests and update systems. That improves operational agility but shifts costs onto private payers, hospitals, or families and reduces some procurement and regulatory oversight that compliance teams typically rely on.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 242 keeps the long-standing legislative intent that the state genetic disease testing program be largely funded from fees but gives the department specific authorities to collect those fees and manage them more tightly. The department must charge fees to “all payers” for any test or activity under the chapter, set amounts by regulation, and periodically adjust fees to cover program costs.
The bill directs the department to move quickly to stand up the fee collection process — hiring staff, contracting, and building data systems as needed.
The bill creates a new Birth Defects Monitoring Program Fund as a sub‑account for prenatal screening fees. It specifies that prenatal screening fees (set in the text at ten dollars) are to be deposited into that fund and that only prenatal screening fees collected before the new fund’s creation and specifically dedicated to Birth Defects Monitoring Program activities may be used from the Genetic Disease Testing Fund for those purposes.
Interest earned on the new fund remains in the fund. The text also reiterates that the department shall charge newborn screening fees to the hospital of birth or, for births outside hospitals, to families — while prohibiting billing Medi‑Cal beneficiaries directly for those services.On research and data access, the department must set invoicing and collection guidelines so approved researchers pay amounts that cover costs tied to application review, data linkage and retrieval, processing, reporting, and shipping of samples or components.
That formalizes a cost‑recovery approach to researcher requests and puts the administrative burden and fees on external users of the stored samples and data.Operationally, AB 242 removes several procurement and IT approval constraints for expenditures from the Genetic Disease Testing Fund. It exempts those expenditures from specified sections of the Public Contract Code and state IT oversight rules in order to permit faster purchase and system upgrades, and it explicitly permits implementing expansions of the Genetic Disease Branch Screening Information System (including specific tests like cystic fibrosis, biotinidase deficiency, SCID, ALD, and Duchenne muscular dystrophy) through contract amendments rather than new competitive procurements.
Finally, the bill authorizes the department to adopt emergency regulations for this program without standard Office of Administrative Law review, to file them immediately with the Secretary of State, to make them effective on filing, and to hold public hearings within 120 days — after which the regulations must either be brought into formal compliance or be repealed.
The Five Things You Need to Know
The bill sets the prenatal screening fee at ten dollars ($10) and requires those fees to be deposited into a newly created Birth Defects Monitoring Program Fund.
The department must charge a fee to all payers for any test or activity under the genetic screening chapter and establish fee amounts by regulation with periodic adjustments to cover costs.
Newborn screening and followup services are billed to the hospital of birth or, for non‑hospital births, to the newborn’s family; the department may not bill Medi‑Cal beneficiaries for those services.
Expenditures from the Genetic Disease Testing Fund for certain testing, equipment, and IT expansions (including adding specific disorders to the screening system) are exempted from named provisions of the Public Contract Code and state IT approval processes and may be implemented through contract amendments.
The department can adopt emergency regulations for the program that bypass Office of Administrative Law review, file directly with the Secretary of State, and take effect immediately, subject to a public hearing within 120 days or repeal.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Legislative intent: fee-supported program
Reaffirms that the genetic disease testing program should be funded by fees collected for services unless stated otherwise. This restatement anchors the rest of the changes in a statutory duty to self‑finance program operations rather than rely on general fund appropriations.
Fee authority and fee‑collection responsibilities
Gives the department express authority to charge fees to all payers for any test or activity under the chapter, requires fees to be set by regulation and adjusted periodically to cover costs, and instructs the department to implement fee collection immediately — including hiring personnel, entering contracts, and building data systems. It also preserves the rule that Medi‑Cal beneficiaries themselves cannot be billed for program services while assigning payment responsibility to payers, hospitals, or families.
Birth Defects Monitoring Program Fund and prenatal fee rules
Creates the Birth Defects Monitoring Program Fund as a special fund to receive prenatal screening fees (specifically set at $10 in the text), requires interest to remain in the fund, and limits which monies from the Genetic Disease Testing Fund may be used for Birth Defects Monitoring Program activities to those prenatal screening fees collected prior to the fund’s creation that were earmarked for those activities. This establishes a ring‑fenced funding stream for pregnancy blood sample storage, testing, and related research.
Research invoicing and cost recovery
Directs the department to set guidelines so approved researchers are invoiced for the full administrative and technical costs of sample and data requests — including application review, data linkage, retrieval, processing, reinventory, reporting, and shipping. Practically, this creates a clear cost‑recovery model for external access to biological samples and linked data and shifts administrative costs to researchers rather than the program’s general operating budget.
Procurement and IT approval exemptions
Authorizes the program to spend Genetic Disease Testing Fund dollars for equipment, data systems, testing equipment, and related services without following named competitive procurement and state IT approval statutes (including certain chapters of the Public Contract Code and state IT project approval rules). It explicitly permits expanding the Genetic Disease Branch Screening Information System to add named disorders via contract amendment rather than a new procurement and exempts maintenance and change requests from routine IT approval processes — speeding implementation but narrowing standard oversight.
Emergency rulemaking and Office of Administrative Law (OAL) process
Permits the department to adopt emergency regulations for the chapter and treats those regulations as necessary for public health and welfare. It removes the requirement that emergency regulations undergo OAL review and instead requires submission directly to the Secretary of State; the regulations take effect on filing but must be subject to public hearing within 120 days and either conformed to APA requirements or repealed. The Office of Administrative Law remains responsible for printing and publishing the regulations and is prohibited from repealing them, leaving durability but also a truncated review window.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Birth Defects Monitoring Program — Gains a dedicated fund and a specified perpetual interest retention mechanism to support pregnancy blood sample storage, testing, reporting, and research activities.
- Department of Public Health — Receives clearer fee authority, a mandate to build fee‑collection infrastructure, and procurement and regulatory flexibilities that speed system expansions and equipment acquisition.
- Researchers (approved applicants) — Get a formalized path to request samples and data, with explicit invoicing rules that clarify costs and administrative expectations (albeit at a price).
Who Bears the Cost
- Hospitals of birth and families (for out‑of‑hospital births) — Face responsibility for newborn screening fees, creating a direct financial obligation for a service historically handled by state programs or bundled into other payments.
- Health plans and private payers — Subject to fee charges for prenatal screening and other tests, potentially increasing claims costs or administrative billing burdens.
- Researchers requesting samples/data — Must pay up‑front to cover full administrative and technical costs, which may price out smaller academic teams or community researchers.
Key Issues
The Core Tension
The central dilemma is straightforward: the bill prioritizes program sustainability and rapid implementation of screening and IT upgrades by shifting costs to payers and reducing procurement and regulatory friction, but those same moves weaken fiscal and procedural oversight and risk imposing burdens on hospitals, families, and researchers — forcing a trade‑off between speed/stability and equity/accountability.
The bill deliberately shifts program sustainability onto fee payers and narrows procurement and regulatory review to accelerate operations. That combination resolves stability and speed problems but creates trade‑offs.
First, moving costs to hospitals, families, or payers raises equity and access questions: out‑of‑pocket or insured billing may create downstream coverage disputes or deter followup care for vulnerable populations. Second, exempting Genetic Disease Testing Fund expenditures and certain IT work from procurement and IT approval statutes reduces competitive sourcing and external oversight, increasing the risk of vendor lock‑in, higher long‑term costs, or insufficient documentation of ‘‘lowest cost consistent with technical requirements,’’ which the department must nonetheless provide to the Department of Finance.
The emergency regulation route compresses administrative review and public notice. Making regulations effective upon Secretary of State filing speeds implementation but shortens the window for meaningful pre‑filing scrutiny and shifts much of the substantive review to a post‑promulgation hearing process.
The bill also creates several implementation tasks with operational complexity: the department must define “all payers,” stand up invoicing and data systems that can route charges to multiple payers and hospitals, and set and periodically adjust fees by regulation in a way that can withstand administrative or legal challenge. Finally, the text’s limitation that only certain pre‑existing prenatal screening fees in the Genetic Disease Testing Fund may be used for Birth Defects Monitoring Program activities raises accounting and transition questions about fund balances and how program costs will be apportioned during the shift.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.